Reimbursement
Tell a friend
Register for updates
Patient Home
Prescribing Information
CORE
Get reimbursement assistance and support with CORE: Cephalon Oncology Reimbursement Expertise
Reimbursement

Review TRISENOX administration and monitoring information
Trisenox Administration Module

Register for updates, request contact from a sales rep or MSL, or request medical, reimbursement, or clinical trials information.


View an animation of the multiple proposed mechanisms of action for TRISENOX


Adverse events reported with TRISENOX

TRISENOX® (arsenic trioxide) injection was generally well tolerated, and most common adverse events usually did not require interruption of therapy.1

Adverse events (AEs) in the U.S. multicenter trial


* Frequency of AEs < 40%
† Frequency of grade 3 and 4 AEs < 5%

>> Click here to review patient management and monitoring guidelines.
1. TRISENOX Prescribing Information. Frazer, Pa: Cephalon, Inc.;2005.
2. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852-3860.
3. Data on file. Cephalon, Inc.

©2008 Cephalon, Inc. All rights reserved.
The information presented on this site is intended for U.S. residents only.
Cephalon Oncology